[
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals: The Cost Of Growing Beyond Cystic Fibrosis (Rating Downgrade)",
    "summary": "Vertex Pharmaceuticals is anchored by cystic fibrosis as launches lag, JOURNAVX and CASGEVY add little revenue, and growth is modest. Read why VRTX stock is a hold.",
    "url": "https://finnhub.io/api/news?id=a22fff21fd0c3cdd7dd06adbb2e2ff7891580bf5113a824f7519e731db0dee25",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767844490,
      "headline": "Vertex Pharmaceuticals: The Cost Of Growing Beyond Cystic Fibrosis (Rating Downgrade)",
      "id": 138032810,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1972334358/image_1972334358.jpg?io=getty-c-w1536",
      "related": "VRTX",
      "source": "SeekingAlpha",
      "summary": "Vertex Pharmaceuticals is anchored by cystic fibrosis as launches lag, JOURNAVX and CASGEVY add little revenue, and growth is modest. Read why VRTX stock is a hold.",
      "url": "https://finnhub.io/api/news?id=a22fff21fd0c3cdd7dd06adbb2e2ff7891580bf5113a824f7519e731db0dee25"
    }
  }
]